Notes from J.P.Morgan Conference 2017: Sequencing (NGS) Moves to Toward Clinical Diagnostic Solutions
Outlook and Issues for Application of NGS for Clinical Diagnostics We heard a few presentations on NGS solutions and still think it is an important growth market for clinical diagnostics in oncology, rare diseases transplant medicine and NIPT. Gene sequencing (NGS) can lead to a better...
Trump Twitter Hangover Keeps Biotech Stocks Down: Update-1
Update-1...1/24/17...Bit of a Rally Leaves Out Healthcare Stocks Markets rallied a bit today but biotech and drug stocks remain stalled by the Trump triggered bashing two weeks ago. Moreover traders are back to nibbling at the infrastructure theme with materials up 2.3% and energy up 1.09%....
2017 J.P.Morgan Healthcare Conference: Large Cap Biotechs Compared to 2016
Large Cap Biopharma Stock Performance YoY from J.P.Morgan Conference The market recovered slightly today from yesterday's "Trump storm" attacking drug prices. The IBB rose 0.36% and the XBI rose 1.56% . The healthcare sector overall was flat. Selected stocks that continued their upward trend...
J.P. Morgan Healthcare Conference Notes #2: Sun is Out but Trump Storm Hits Biotech Stocks
Biotech Rally Snuffed Out Again By Tough Trump Talk on Drug Pricing Any market optimism from the Conference about new product pipelines, M&A and "read-outs" on clinical data was chilled by Trump's idea to let Medicare negotiate for better drug prices a perennial idea by DEMs in previous...
2017 J.P.Morgan Healthcare Conference Notes #1: Investors Buy Selective Biotech Stocks-ILMN, INCY, REGN,RDUS
Wet Stormy Weather in San Francisco-A New Indicator for a Good Year Ahead? About 8000+ investors, entrepreneurs and life science Company executives piled into the Westin St. Francis for the Annual J.P.Morgan Healthcare Conference and maybe 10k+ others at several other surrounding hotel venues...